

DAFTAR PUSTAKA

1. World Health Organization. HIV and AIDS. 2023.
2. Arifin B, Rokhman MR, Zulkarnain Z, Perwitasari DA, Mangau M, Rauf S, et al. The knowledge mapping of HIV/AIDS in Indonesians living on six major islands using the Indonesian version of the HIV-KQ-18 instrument. Fauk NK, editor. PLoS One. 2023 Nov;18(11):e0293876.
3. Data Sistem Informasi HIV AIDS. Padang; 2023.
4. Bhatt A, Quazi Syed Z, Singh H. Converging Epidemics: A Narrative Review of Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) Coinfection. Cureus. 2023 Oct;15(10):e47624.
5. Sharan R, Buçsan AN, Ganatra S, Paiardini M, Mohan M, Mehra S, et al. Chronic Immune Activation in TB/HIV Co-infection. Trends Microbiol. 2020 Aug;28(8):619–32.
6. Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, et al. Tuberculosis. In: Disease Control Priorities, Third Edition (Volume 6): Major Infectious Diseases. The World Bank; 2017. p. 233–313.
7. Seth P. The Situation of HIV/M. tuberculosis Co-Infection in India. Open Infect Dis J. 2011 Jul;5(1):51–9.
8. World Health Organization. Global Tuberculosis Report. 2023;
9. Lestari T, Fuady A, Yani FF, Putra IWGAE, Pradipta IS, Chaidir L, et al. The development of the national tuberculosis research priority in Indonesia: A comprehensive mixed-method approach. PLoS One. 2023;18(2):e0281591.
10. Dinas Kesehatan Kota Padang. Profil Kesehatan Kota Padang Tahun 2022. 2023.
11. Takhar RP, Mirdha K, Purohit G, Maan L, Bainara MK. Impact of HIV Co-Infection on Clinical Presentation in Patients with TB and Correlation of the Findings with Level of Immune Suppression. Tanaffos. 2018 Mar;17(3):188–97.
12. Faria MGBF de, Andrade RL de P, Camillo AJG, Leite KF de S, Saita NM, Bollela VR, et al. Efetividade do GeneXpert® no diagnóstico da tuberculose em pessoas que vivem com HIV/aids. Rev Saude Publica. 2021 Dec;55:89.



13. Saeed M, Hussain S, Riaz S, Rasheed F, Ahmad M, Iram S, et al. GeneXpert Technology for the diagnosis of HIV-associated tuberculosis: Is scale-up worth it? *Open life Sci.* 2020;15(1):458–65.
14. Havlir D V, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. *N Engl J Med.* 2011 Oct;365(16):1482–91.
15. World Health Organization. WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 2021 update. 2021. 162 p.
16. World Health Organization. WHO operational handbook on tuberculosis: module 2: screening: systematic screening for tuberculosis disease. 2022. 124 p.
17. Correia-Neves M, Fröberg G, Korshun L, Viegas S, Vaz P, Ramanlal N, et al. Biomarkers for tuberculosis: the case for lipoarabinomannan. *ERJ Open Res.* 2019 Feb;5(1):00115–2018.
18. Wood R, Racow K, Bekker LG, Middelkoop K, Vogt M, Kreiswirth BN, et al. Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria. *BMC Infect Dis.* 2012 Dec;12(1):47.
19. Margono D, Ningtias PY, Kusumaningrum A, Prasetyo DS. The use of urine lipoarabinomannan for establishing pulmonary TB in HIV patient: case report and systematic review. *J Clin Microbiol Infect Dis.* 2023;3(2):45–8.
20. Agha MA, El-Helbawy RH, El-Helbawy NG, El-Sheak NM. Utility of quantitative analysis of urine lipoarabinomannan in the diagnosis of tuberculosis. *Egypt J Chest Dis Tuberc.* 2013 Jul;62(3):401–7.
21. Kumar A. The Diagnostic and Prognostic Value of Urine Lipoarabinomannan in Extrapulmonary Tuberculosis: A Review of Current Evidence. *Medicon Med Sci.* 2023 Sep;5(4):2–5.
22. Lawn SD, Kerkhoff AD, Vagt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. *Lancet Infect Dis.* 2012;12:201–9.

23. Simanjuntak RB. Uji Diagnostik Lipoarbinomannan (LAM) Urine pada Pasien Terduga Tuberkulosis Paru Pasien HIV/AIDS. Universitas Andalas; 2017.
24. Gao M, Wu Q, Wang X, Sun X, Li M, Bai G. Advancements in LAM-based diagnostic kit for tuberculosis detection: enhancing TB diagnosis in HIV-negative individuals. *Front Microbiol.* 2024 Feb;15:1367092.
25. Zhang Y, Chen S, Wei H, Zhong Q, Yuan Y, Wang Y, et al. Breakthrough of chemiluminescence-based LAM urine test beyond HIV-positive individuals: Clinical diagnostic value of pulmonary tuberculosis in the general population. *Medicine (Baltimore).* 2023 Dec;102(48):e36371.
26. Simienh A, Tadesse M, Kebede W, Gashaw M, Abebe G. Combination of Xpert® MTB/RIF and Determine™ TB-LAM Ag improves the diagnosis of extrapulmonary tuberculosis at Jimma University Medical Center, Oromia, Ethiopia. Anupurba S, editor. *PLoS One.* 2022 Feb;17(2):e0263172.
27. Human Immunodeficiency Virus (HIV). *Transfus Med Hemotherapy.* 2016;43(3):203–22.
28. Masenga SK, Mweene BC, Luwaya E, Muchaili L, Chona M, Kirabo A. HIV–Host Cell Interactions. *Cells.* 2023 May;12(10):1351.
29. World Health Organization. HIV. 2023.
30. World Health Organization. HIV statistics, globally and by WHO region, 2023. 2023.
31. Kementerian Kesehatan RI. Laporan Eksekutif Perkembangan HIV AIDS dan Penyakit Infeksi Menular Seksual (PMS) Triwulan I Tahun 2023. 2023.
32. Ratnam M, Nayyar A, Reddy Ds, Ruparani B, Chalapathi K, Md S. CD4 cell counts and oral manifestations in HIV infected and AIDS patients. *J Oral Maxillofac Pathol.* 2018;22(2):282.
33. Setiawati S, Alwi I, Sudoyo AW, Simadibrata MK, Setiyohadi B, Syam AF. Buku Ajar Ilmu Penyakit Dalam Edisi VI. InternaPublishing; 2014. 887–896 p.
34. Siddiqui S, Perez S, Gao Y, Doyle-Meyers L, Foley B, Li Q, et al. Persistent Viral Reservoirs in Lymphoid Tissues in SIV-Infected Rhesus Macaques of

- Chinese-Origin on Suppressive Antiretroviral Therapy. *Viruses*. 2019 Jan;11(2):105.
35. Chen J, Zhou T, Zhang Y, Luo S, Chen H, Chen D, et al. The reservoir of latent HIV. *Front Cell Infect Microbiol*. 2022 Jul;12.
 36. Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. *Nat Rev Dis Prim*. 2015 Oct;1(1):15035.
 37. Prins HAB, Rokx C, Verbon A, van Sighem A, de Bree GJ, Dijkstra M, et al. HIV transmission among acutely infected participants of a Dutch cohort study 2015–2021 is not associated with large, clustered outbreaks. *AIDS*. 2023 Feb;37(2):299–303.
 38. sharafi M, Mirahmadizadeh A, Hassanzadeh J, Seif M, Heiran A. Factors associated with late initiation of antiretroviral therapy in Iran's HIV/AIDS surveillance data. *Sci Rep*. 2024 Jan;14(1):199.
 39. Huynh K, Kahwaji CI. HIV Testing. *StatPearls*. 2024.
 40. Gannon-Loew KE, Holland-Hall C. A review of current guidelines and research on the management of sexually transmitted infections in adolescents and young adults. *Ther Adv Infect Dis*. 2020 Jan;7:204993612096066.
 41. Terracciano E, Amadori F, Zaratti L, Franco E. [Tuberculosis: an ever present disease but difficult to prevent]. *Ig Sanita Pubbl*. 2020;76(1):59–66.
 42. Tobin EH, Tristram D. Tuberculosis. *StatPearls*. 2024.
 43. Jilani TN, Avula A, Zafar Gondal A, Siddiqui AH. Active Tuberculosis. *StatPearls*. 2024.
 44. Noviyani A, Nopsopon T, Pongpirul K. Variation of tuberculosis prevalence across diagnostic approaches and geographical areas of Indonesia. Quinn F, editor. *PLoS One*. 2021 Oct;16(10):e0258809.
 45. Alsayed SSR, Gunosewoyo H. Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. *Int J Mol Sci*. 2023 Mar;24(6).
 46. Luies L, du Preez I. The Echo of Pulmonary Tuberculosis: Mechanisms of Clinical Symptoms and Other Disease-Induced Systemic Complications. *Clin Microbiol Rev*. 2020 Sep;33(4).
 47. Ryu YJ. Diagnosis of Pulmonary Tuberculosis: Recent Advances and Diagnostic Algorithms. *Tuberc Respir Dis (Seoul)*. 2015;78(2):64.

48. Kementrian Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia No. 67 Tahun 2016 Tentang Pengendalian Tuberkulosis. 2016;
49. Rasool G, Khan AM, Mohy-Ud-Din R, Riaz M. Detection of Mycobacterium tuberculosis in AFB smear-negative sputum specimens through MTB culture and GeneXpert ® MTB/RIF assay. *Int J Immunopathol Pharmacol*. 2019 Jan;33:205873841982717.
50. Meka DM. Diagnostic Accuracy of Gene Xpert vs Acid Fast Smear in HIV Patients Suspected for Tuberculosis. *J Med Sci Clin Res*. 2020 Jan;08(01):125–31.
51. Susilawati TN, Larasati R. A recent update of the diagnostic methods for tuberculosis and their applicability in Indonesia: a narrative review. *Med J Indones*. 2019 Oct;28(3):284–91.
52. Haraka F, Kakolwa M, Schumacher SG, Nathavitharana RR, Denkinger CM, Gagneux S, et al. Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis. *Cochrane Database Syst Rev*. 2021 May;2021(5).
53. Nathavitharana RR, Lederer P, Chaplin M, Bjerrum S, Steingart KR, Shah M. Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV. *Cochrane database Syst Rev*. 2021 Aug;8(8):CD014641.
54. Benjamin A, Cavalcante SC, Jamal LF, Arakaki-Sanchez D, de Lima JN, Pilotto JH, et al. Accuracy of Determine TB-LAM Ag to detect TB in HIV infected patients associated with diagnostic methods used in Brazilian public health units. Verdonck K, editor. *PLoS One*. 2019 Sep;14(9):e0221038.
55. Cox JA, Lukande RL, Kalungi S, Van Marck E, Van de Vijver K, Kambugu A, et al. Is Urinary Lipoarabinomannan the Result of Renal Tuberculosis? Assessment of the Renal Histology in an Autopsy Cohort of Ugandan HIV-Infected Adults. Sands JM, editor. *PLoS One*. 2015 Apr;10(4):e0123323.
56. Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, Kraus S, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. *Eur Respir J*. 2012 Nov;40(5):1211–20.

57. Goletti D, Pisapia R, Fusco FM, Aiello A, Van Crevel R. Epidemiology, pathogenesis, clinical presentation and management of TB in patients with HIV and diabetes. *Int J Tuberc Lung Dis.* 2023 Apr;27(4):284–90.
58. Ansari AW, Kamarulzaman A, Schmidt RE. Multifaceted Impact of Host C–C Chemokine CCL2 in the Immuno-Pathogenesis of HIV-1/M. tuberculosis Co-Infection. *Front Immunol.* 2013;4:312.
59. Bruchfeld J, Correia-Neves M, Källenius G. Tuberculosis and HIV Coinfection. *Cold Spring Harb Perspect Med.* 2015 Jul;5(7):a017871.
60. Wong K, Nguyen J, Blair L, Banjanin M, Grewal B, Bowman S, et al. Pathogenesis of Human Immunodeficiency Virus-Mycobacterium tuberculosis Co-Infection. *J Clin Med.* 2020 Nov;9(11).
61. Diedrich CR, O'Hern J, Wilkinson RJ. HIV-1 and the Mycobacterium tuberculosis granuloma: A systematic review and meta-analysis. *Tuberculosis.* 2016 May;98:62–76.
62. Zhang W, Ruan L. Recent advances in poor HIV immune reconstitution: what will the future look like? *Front Microbiol.* 2023 Aug;14.
63. Getaneh Y, Khairunisa SQ, Husada D, Kuntaman K, Lusida MI. Impact TB co-infections on immune tolerance among people living with HIV: a systematic review. *HIV Res Clin Pract.* 2023;24(1):2270822.
64. Seid A, Girma Y, Abebe A, Dereb E, Kassa M, Berhane N. Characteristics of TB/HIV Co-Infection and Patterns of Multidrug-Resistance Tuberculosis in the Northwest Amhara, Ethiopia. *Infect Drug Resist.* 2023;16:3829–45.
65. Yang Q, Han J, Shen J, Peng X, Zhou L, Yin X. Diagnosis and treatment of tuberculosis in adults with HIV. *Med.* 2022;101(35):e30405.
66. World Health Organization. TB-HIV Co-infection. 2019.
67. Yoon C, Semitala FC, Asege L, Katende J, Mwebe S, Andama AO, et al. Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV. *Am J Respir Crit Care Med.* 2019 Mar;199(5):643–50.
68. Gupta-Wright A, Corbett EL, Wilson D, van Oosterhout JJ, Dheda K, Huerga H, et al. Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated

- tuberculosis in sub-Saharan Africa: Derivation and external validation cohort study. Hatherill M, editor. *PLOS Med*. 2019 Apr;16(4):e1002776.
69. Monkongdee P, McCarthy KD, Cain KP, Tasaneeyapan T, Dung NH, Lan NTN, et al. Yield of Acid-fast Smear and Mycobacterial Culture for Tuberculosis Diagnosis in People with Human Immunodeficiency Virus. *Am J Respir Crit Care Med*. 2009 Nov;180(9):903–8.
 70. Ssengooba W, Kiwanuka N, Kateete DP, Katamba A, Joloba ML. Incremental Yield of Serial Sputum Cultures for Diagnosis of Tuberculosis among HIV Infected Smear Negative Pulmonary TB Suspects in Kampala, Uganda. Hoshino Y, editor. *PLoS One*. 2012 May;7(5):e37650.
 71. Bulterys MA, Wagner B, Redard-Jacot M, Suresh A, Pollock NR, Moreau E, et al. Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update. *J Clin Med*. 2019 Dec;9(1):111.
 72. Krishna S, Ray A, Dubey SK, Larrouy-Maumus G, Chalut C, Castanier R, et al. Lipoglycans contribute to innate immune detection of mycobacteria. *PLoS One*. 2011;6(12):e28476.
 73. Shi L, Torrelles JB, Chatterjee D. Lipoglycans of *Mycobacterium tuberculosis*: Isolation, Purification, and Characterization. In 2009. p. 23–45.
 74. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. *BMC Infect Dis*. 2012 Dec;12(1):103.
 75. Flores J, Cancino JC, Chavez-Galan L. Lipoarabinomannan as a Point-of-Care Assay for Diagnosis of Tuberculosis: How Far Are We to Use It? *Front Microbiol*. 2021 Apr;12.
 76. Elhalawany N, Shalaby N, Fathy A, Elmorsy AS, Zaghloul M, El-shahawy H, et al. Role of detection of lipoarabinomannan (LAM) in urine for diagnosis of pulmonary tuberculosis in HIV patients: Egyptian experience. *Egypt J Bronchol*. 2021 Dec;15(1):20.
 77. Puspita S, Turbawaty DK, Tristina N, Lismayanti L. Positive Lateral Flow Urine Lipoarabinomannan Assay (LF-LAM) Result in Detection of Active Tuberculosis. *Maj Kedokt Bandung*. 2021 Sep;53(3):169–73.

78. Busch M, Herzmann C, Kallert S, Zimmermann A, Höfer C, Mayer D, et al. Lipoarabinomannan-Responsive Polycytotoxic T Cells Are Associated with Protection in Human Tuberculosis. *Am J Respir Crit Care Med*. 2016 Aug;194(3):345–55.
79. Brock M, Hanlon D, Zhao M, Pollock NR. Detection of mycobacterial lipoarabinomannan in serum for diagnosis of active tuberculosis. *Diagn Microbiol Infect Dis*. 2020 Feb;96(2):114937.
80. Liu D, Gu L, Zhang R, Liu L, Shen Y, Shao Y, et al. Utility of urine lipoarabinomannan (LAM) in diagnosing mycobacteria infection among hospitalized HIV-positive patients. *Int J Infect Dis*. 2022;118:65–70.
81. Huerga H, Rucker SCM, Bastard M, Dimba A, Kamba C, Amoros I, et al. Should Urine-LAM Tests Be Used in TB Symptomatic HIV-Positive Patients When No CD4 Count Is Available? A Prospective Observational Cohort Study from Malawi. *J Acquir Immune Defic Syndr*. 2020;83(1):24–30.
82. Ganesan K, Mwesigwa R, Dear N, Esber AL, Reed D, Kibuuka H, et al. Epidemiology of Tuberculosis Among People Living With HIV in the African Cohort Study From 2013 to 2021. *J Acquir Immune Defic Syndr*. 2023;92(5):359–69.
83. Govender RD, Hashim MJ, Khan MA, Mustafa H, Khan G. Global Epidemiology of HIV/AIDS: A Resurgence in North America and Europe. *J Epidemiol Glob Health*. 2021;11(3):296–301.
84. Rohmatullailah D, Fikriyah D. Faktor Risiko Kejadian HIV Pada Kelompok Usia Produktif di Indonesia. *J Biostat Kependudukan, dan Inform Kesehat*. 2021;2(1):45.
85. Tanjung HY, Ismah Z, Susanti N. Epidemiologi HIV di Kota Medan Tahun 2021 - 2023. *Malahayati Heal Student J*. 2024;
86. Belew H, Wubie M, Tizazu G, Bitew A, Birlew T. Predictors of tuberculosis infection among adults visiting anti-retroviral treatment center at east and west Gojjam, northwest, Ethiopia, 2017. *BMC Infect Dis*. 2020;20(1):1–10.
87. Mwatenga SA, Musa AA, Muturi MW, Musyoki AM. Prevalence and associated factors of TB and HIV coinfections among adult inmates with

- presumptive pulmonary TB in a Kenyan prison. *Trop Med Health*. 2024;52(1).
88. Kouhpayeh H. Different diets and their effect on tuberculosis prevention in HIV patients. *J Fam Med Prim Care*. 2022;1369–76.
 89. Carwile ME, Hochberg NS, Sinha P. Undernutrition is feeding the tuberculosis pandemic: A perspective. *J Clin Tuberc Other Mycobact Dis*. 2022;27:100311.
 90. Songkhla MN, Tantipong H, Tongchai S, Angkasekwinai N. Lateral flow urine lipoarabinomannan assay for diagnosis of active tuberculosis in adults with human immunodeficiency virus infection: A prospective cohort study. *Open Forum Infect Dis*. 2019;6(4):1–8.
 91. Mi Y, Zhou M, Zeng Y, Wang P, Gao L, Cheng F. Factors Associated With Delayed and Late Initiation of Antiretroviral Therapy Among Patients With HIV in Beijing, China, 2010–2020. *Int J Public Health*. 2023;68(June):1–9.
 92. Serra MAAO, Milhomem AB, Oliveira SB, Santos FAAS, Silva RAE, Costa ACPJ, et al. Sociodemographic and Behavioral Factors Associated with HIV Vulnerability according to Sexual Orientation. *AIDS Res Treat*. 2020;2020.
 93. Gruszczyńska E, Rzeszutek M. HIV/AIDS stigma accumulation among people living with HIV: a role of general and relative minority status. *Sci Rep*. 2023;13(1):10709.
 94. Bunting SR, Feinstein BA, Hazra A, Garber SS. Effects of Patient Sexual Orientation and Gender Identity on Medical Students' Decision Making Regarding Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention: A Vignette-Based Study. *Sex Transm Dis*. 2021;48(12):959–66.
 95. Ribeiro Banze Á, Muleia R, Nuvunga S, Boothe M, Semá Baltazar C. Trends in HIV prevalence and risk factors among men who have sex with men in Mozambique: implications for targeted interventions and public health strategies. *BMC Public Health*. 2024;24(1):1–9.
 96. Hanin L, Rahmawati YW, Djalilah GN, Subagyo R. Hubungan Perilaku Seksual Berisiko dengan Kejadian HIV / AIDS Pada Laki Laki The Relationship between Risky Sexual Behavior With the Incidence Of HIV /

- AIDS Among Men Who Have Sex With Men. *J Implementa Husada*. 2021;2(1).
97. Kakoma LN, Mukesi M, Moyo SR. Effectiveness of GeneXpert technology in the diagnosis of smear-negative pulmonary mycobacterium tuberculosis in HIV positive patients in Namibia. *Open J Med Microbiol*. 2016; 6: 133-41.
 98. Wandrivel R. Nilai Diagnostik Aktivitas Indoleamine 2,3-Dioxygenase 1 Plasma Untuk Mendiagnosis Tuberkulosis Paru Aktif Pada Pasien HIV. *UNAND*. 2022
 99. Benjamin A, Cavalcante SC, Jamal LF, Arakaki-Sanchez D, De Lima JN, Pilotto JH, et al. Accuracy of Determine TB-LAM Ag to detect TB in HIV infected patients associated with diagnostic methods used in Brazilian public health units. *PLoS One*. 2019;14(9):1–10.
 100. Afrashteh S, Fararouei M, Ghaem H, Aryaie M. Factors Associated with Baseline CD4 Cell Counts and Advanced HIV Disease among Male and Female HIV-Positive Patients in Iran: A Retrospective Cohort Study. *J Trop Med*. 2022;2022.
 101. Sabur NF, Esmail A, Brar MS, Dheda K. Diagnosing tuberculosis in hospitalized HIV-infected individuals who cannot produce sputum: is urine lipoarabinomannan testing the answer ?. *BMC Infect Dis*. 2017; 17: 1–6
 102. Brock M, Hanlon D, Zhao M, Pollock NR. Detection of mycobacterial lipoarabinomannan in serum for diagnosis of active tuberculosis. *Diagn Microbiol Infect Dis*. 2020;96(2):114937
 103. Matoga MM, Bisson GP, Gupta A, Miyahara S, Sun X, Fry C, et al. Urine Lipoarabinomannan Testing in Adults with Advanced Human Immunodeficiency Virus in a Trial of Empiric Tuberculosis Therapy. *Clin Infect Dis*.

2021;73(4):E870–7.

104. Kerkhoff AD, Wood R, Vogt M, Lawn SD. Prognostic value of a quantitative analysis of lipoarabinomannan in urine from patients with HIV-associated tuberculosis. PLoS One. 2014;9(7).

